Status: Recruiting
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).
Participants needed: 48
Trial details
Phase: Phase 2Age: 12-75Biological sex: AllType: InterventionalSponsor: Angitia Biopharmaceuticals Guangzhou LimitedUpdated: Jun 22, 2026Locations: 4
Eligibility criteria
Adults (18-75 years) or adolescents (12-17 years) with a confirmed diagnosis of... [+2]
Vitamin D deficiency [+10]